New development partnership aims to revolutionize breast cancer diagnosis|Andrew Newland, CEO, Angle PLC. 00:10:00
Development partnership announced to create circulating tumor cell HER2 assay for breast cancer, potentially revolutionizing global access to technology measuring HER2 status.